Veradermics, Inc (MANE): Cash & Equivalents
$21.77M
As of 2025-12-31
$319.33M
As of 2026-06-30
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $21.77M | -59.0% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $53.08M | n/a | 2026-03-30, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Veradermics, Inc (MANE) | 2025-12-31 | $21.77M | -59.0% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $12.67M | -66.7% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $13.15M | -50.0% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $37.57M | +31.0% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $137.53M | +148.7% |
| XBiotech Inc. (XBIT) | 2025-12-31 | $125.55M | -27.3% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $30.23M | +2.4% |
| Boundless Bio, Inc. (BOLD) | 2025-12-31 | $17.87M | -32.8% |
| Larimar Therapeutics, Inc. (LRMR) | 2025-12-31 | $85.41M | +157.1% |
Compare MANE, CTMX, OVID, WHWK side by side · Screen every company in Pharmaceutical Preparations ↗